Abstract
Purpose:
To detail surgical strategy and strabismus outcomes in a genetically defined cohort of congenital fibrosis of the extraocular muscles (CFEOM) patients.
Methods:
A total of 13 patients with genetically confirmed CFEOM (via genetic testing for mutations in KIF21A, PHOX2A, and TUBB3) were retrospectively identified after undergoing strabismus surgery at a tertiary care referral center and their surgical outcomes were compared.
Results:
Age at first surgery ranged from 11 months to 63 years with an average of 3 strabismus procedures per patient. Ten patients had CFEOM1, of whom 9 had the KIF21A R954W amino acid (AA) substitution while 1 had the M947T AA substitution. Of the 3 with CFEOM3, 2 had the TUBB3 E410K AA substitution, and 1 had a previously unreported E410V AA substitution. CFEOM1 patients all underwent at least 1 procedure to address chin-up posture. Chin-up posture improved from 24° (± 8°) before surgery to 10.0° (± 8°) postoperatively (P < 0.001). Three CFEOM1 patients developed exotropia after vertical muscle surgery alone; all had the R954W AA substitution. Postoperatively, 1 CFEOM1 patient developed a corneal ulcer. All CFEOM3 patients appeared to have underlying exposure keratopathy, successfully treated with prosthetic replacement of the ocular surface ecosystem (PROSE) lens in 2 patients.
Conclusions:
CFEOM is a complex strabismus disorder for which surgical management is difficult. Despite an aggressive surgical approach, multiple procedures may be necessary to achieve a desirable surgical effect. Knowledge of the underlying genetic diagnosis may help to inform surgical management and thus serve to improve outcomes.
Congenital fibrosis of the extraocular muscles (CFEOM) refers to several rare strabismus disorders, generally characterized by non-progressive blepharoptosis and ophthalmoplegia with restricted vertical gaze and variably restricted horizontal gaze. Three clinical phenotypes of CFEOM have been reported: CFEOM1, 2, and 3. CFEOM1 results primarily from heterozygous mutations in KIF21A,(1) CFEOM2 from homozygous mutations in PHOX2A,(2) and CFEOM3 from heterozygous mutations in TUBB3 and rarely in KIF21A or TUBB2B.(1–5) Mouse models of CFEOM have revealed that the strabismus phenotype results from dysinnervation of the extraocular muscles that normally receive innervation from the oculomotor or trochlear nerves.(4, 6, 7) CFEOM thus falls within the broad spectrum of the congenital cranial dysinnervation disorders (CCDDs).(8–10)
Surgical management of strabismus in patients with CFEOM is difficult given the complexity of the disease process. Patients may have profound limitation of eye movements, severely anomalous compensatory head postures, and aberrant innervation that may lead to unexpected surgical results. Surgical treatments have varied dramatically, and, in the literature, few reports provide a detailed surgical approach and sensorimotor outcomes.(11–20) Furthermore, among the cohorts examined to date, patients have been defined on the basis of clinical criteria without genetic confirmation of diagnosis or stratification.
We hypothesized that knowledge of the mutation underlying the clinical presentation of an individual patient could provide additional information or perspective for a surgeon considering a corrective procedure on a CFEOM patient. The purpose of this study is to describe the surgical results in a genetically defined population of CFEOM patients in an effort to examine whether genetic stratification was relevant for surgical planning or would lead to more predictable surgical outcomes. We evaluated this within each genetically defined subtype, i.e., within the CFEOM1 group and the CFEOM3 group. Further, with this genetic categorization, we sought to determine the differences in surgical outcomes and specific surgical considerations between patients with CFEOM1 and CFEOM3, which to date has not been performed.
METHODS
This study was approved by our Institutional Review Board and conducted in compliance with the Health Insurance Portability and Accountability Act. A retrospective chart review of all patients with a diagnosis of CFEOM seen in the Department of Ophthalmology from January 1992 to September 2018 was performed. Patients were included in the study if they had undergone at least one strabismus surgery for CFEOM at our institution and had a genetically confirmed diagnosis (i.e., genetic testing for mutations in KIF21A, PHOX2A, and TUBB3 had been undertaken either as part of clinical testing and/or through a research-based protocol), as previously described.(1, 2, 4)
The practice for clinical evaluation of CFEOM patients at our pediatric hospital included assessment of ocular alignment at both distance and near, using alternate prism and cover testing where appropriate. In cases of limited cooperation or extremely limited ocular motility, Krimsky light reflex testing was used to approximate the angle of strabismus. Anomalous head positions were measured in degrees, using a goniometer by evaluating the position when fixating at distance or using external photographs of the subject when goniometer measurements were not available. The goniometer was positioned to allow for measurements of chin-up or -down head positions as well as for head turns right or left.(21)
Statistical analysis of changes in head position was performed using IBM SPSS Statistics for Windows (Version 23.0. IBM Corp, Armonk, NY). A Student t-test was used to compare mean angle for pre- and postoperative head position.
RESULTS
The genetic database record review identified 13 patients who met inclusion criteria (Table 1). The cohort consisted of 7 male and 6 female patients, with an age at first surgery ranging from 11 months to 63 years. Of these patients, 10 harbored a mutation in the CFEOM1 KIF21A gene and 3 patients harbored a mutation in the CFEOM3 TUBB3 gene. No patients in our group had CFEOM2.
Table 1.
Patient demographics and genetic diagnoses
| Patient number | Age at first surgery (years) | Sex | Amino acid substitution | Total number of strabismus procedures | Eyelid surgery | Outcome AHP/strabismus |
|---|---|---|---|---|---|---|
| CFEOM 1 Patients | ||||||
| 1a | 2 | F | R954W | 1 | No | + + / − |
| 2a | 46 | M | R954W | 1 | No | + / − |
| 3b | 31 | F | R954W | 2 | No | + + / − |
| 4b | 63 | M | R954W | 1 | No | + / + |
| 5 | 3 | F | R954W | 2 | Yes | + / NA |
| 6 | 6 | F | R954W | 3 | No | + + / ++ |
| 7 | 2 | M | R954W | 2 | Yes | + + / NA |
| 8 | 1 | M | R954W | 2 | Yes | + / ++ |
| 9 | 5 | F | R954W | 1 | Yes | + + / ++ |
| 10 | 1 | M | M947T | 12 | Yes | − / + + |
| CFEOM 3 Patients | ||||||
| 11 | 2 | M | E410K | 5 | Yes | − / − |
| 12 | 1 | F | E410K | 2 | Yes | NA / + + |
| 13 | 8 | M | E410V | 2 | No | ++ / ++ |
Grading system for anomalous head posture (AHP): + indicates 10 degrees of improvement; ++ indicates within 5 degrees of primary position; - indicates no improvement; NA indicates that head posture was not a preoperative concern. Grading system for strabismus: + indicates 10 prism diopters of improvement; ++ indicates strabismus ≤10 prism diopters of primary position; - indicates no improvement or overcorrection of ≥10 prism diopters; NA indicates that strabismus was not a preoperative concern.
Patients 1 and 2 are from the same family
Patients 3 and 4 are from the same family
CFEOM1 group
Of the 10 patients with CFEOM1, 9 carried the R954W amino acid (AA) substitution, which is the most commonly reported CFEOM1 substitution in the KIF21A gene.(1, 22) The remaining patient had the less common M947T AA substitution, and details of this patient were previously reported by Yamada et al. for the association of CFEOM and Marcus Gunn jaw winking.(23) Prior to presentation at our institution, two patients (patient 3 and patient 10, see Table 1) had undergone strabismus surgery; one had 4 previous procedures and the other had 1 previous surgery.
The majority of the CFEOM1 cohort had a significant chin-up posture secondary both to inability to elevate the eyes to midline and to bilateral blepharoptosis. The surgical interventions to address this head position were varied and included large inferior rectus recessions, inferior rectus myectomies, superior oblique tenotomies, and superior rectus strengthening procedures. These details are listed in Table 2.
Table 2.
Surgical treatments for chin-up head posture in CFEOM 1 patients
| Patient number | Procedure | ||||
|---|---|---|---|---|---|
| Bilateral SO tenotomies | IR recession ≥ 11mm | Bilateral IR myectomy | Other IR weakeninga | SR plication or resection | |
| 1 | − | − | + | − | − |
| 2 | + | − | + | − | − |
| 3 | + | − | − | + | − |
| 4 | + | + | − | − | − |
| 5 | − | − | − | + | + |
| 6 | − | + | − | − | − |
| 7 | + | − | − | + | + |
| 8 | + | + | − | − | + |
| 9 | − | + | − | − | − |
| 10 | + | − | − | + | − |
| Total n (%) | 6 (60) | 4 (40) | 2 (20) | 4 (40) | 3 (30) |
SO = superior oblique; IR = inferior rectus; SR = superior rectus.
Other IR weakening procedures included small recessions and transposition of the IR to the orbital wall.
Head position data pre- and post-surgery were available for 8 CFEOM1 patients (Figure 1). Chin-up head position improved in these patients, from 24.4° (± 7.8°) before surgery to 10.0° (± 7.5°) postoperatively (P < 0.001).
Figure 1. Change in head position after surgery for CFEOM1.

In these box-and-whiskers plots, the bottom and top of each box represent the 25th and 75th percentiles (the lower and upper quartiles, respectively); the band near the middle of the box is the 50th percentile (the median). The circle denotes an outlier.
With respect to preoperative horizontal alignment, 3 of the CFEOM1 patients had esotropia, 2 had exotropia (including the patient with the M479T substitution), and 5 had minimal horizontal strabismus (≤10Δ). Of those without initial strabismus, three developed a postoperative exotropia after vertical strabismus surgery, two of whom (patient 6 and patient 8) subsequently underwent horizontal strabismus surgery with excellent postoperative alignment. Postoperative results are summarized in Table 1.
In our CFEOM1 cohort, surgery to address blepharoptosis was performed in half of the patients. Patients 7, 8, and 9 underwent frontalis slings with silicone rod suspension, and patient 5 underwent frontalis slings with autologous fascia lata. In addition, patient 10 underwent bilateral levator resections prior to seeking treatment at our institution. Patient 7 had an infection of a silicone rod of the left upper eyelid prior to presentation at our institution, and this required removal. To date, no patient in our cohort has required a revision of eyelid surgery performed at our institution and no patient has experienced exposure keratopathy consequent to the eyelid procedure.
CFEOM1 patient 3 developed a post-strabismus surgery corneal ulcer despite having undergone no eyelid surgery. The development of the ulcer was noted approximately 5 weeks following strabismus surgery and was not associated with any peri-operative injury. Rather, the patient appeared to have bilateral superficial punctate keratopathy of the inferior corneal surface noted in the immediate post-operative period which was treated with topical antibiotic ointment. Nevertheless, a small inferior and peripheral corneal ulcer developed in the right eye which was treated with topical antibiotic eye drops and ointment. The patient was followed closely with complete resolution of the ulcer by the two-week follow up after initiation of treatment. No other corneal complications were noted in this group.
CFEOM3 group
Of the 3 patients with CFEOM3, patients 11 and 12 harbored the previously reported heterozygous TUBB3 E410K AA substitution,(4) and patient 13 harbored a previously unreported TUBB3 E410V AA substitution. Patient 13’s presentation was similar to that described for the TUBB3 E410K AA substitution,(4, 24) including CFEOM, facial weakness, Kallmann syndrome, and developmental delay; he had been presumed to have atypical Moebius syndrome prior to definitive genetic testing for CFEOM3 (see eSupplement for the full clinical report). Patient 11 underwent 11-mm bilateral inferior rectus recessions for a chin-up head position estimated at 20°, which improved to head position to 0° postoperatively. Patient 13, with the E410V AA substitution and who presented elsewhere without a chin-up head posture, nonetheless underwent 10 mm superior oblique recessions at that center due to an anomalous superior oblique muscle found at the time of surgery. His head posture is excellent, within 5° of primary position (see Table 1)
All 3 CFEOM3 patients had large exodeviations at birth and underwent their initial surgeries at age 1 year or younger. Lateral rectus recessions alone were ineffective at correcting the horizontal alignment and, in each case, transposition of the lateral rectus muscle to the orbital rim was eventually performed.(25) Patient 11 had 14-mm bilateral lateral rectus recessions for an exotropia of 80Δ. This patient was treated with numerous botulinum toxin injections and finally a transposition to the orbital rim, with a modest improvement in the exotropia to 50Δ. He did not undergo any medial rectus strengthening procedures. At most recent follow-up, the exotropia had recrudesced to 80Δ, and the family was not interested in pursuing further surgery. Patient 12 had bilateral fixation of the lateral rectus muscles to the orbital rim. This was combined with nasal transposition of the superior oblique muscles. For this procedure, the superior oblique tendon was disinserted, transposed, and fixed immediately superior and anterior to the medial rectus insertion to bring the eye into an adducted position. This approach reduced the exotropia from 75Δ to 16Δ over 8 years of follow-up. Patient 13, with the E410V AA substitution, presented with a 90Δ exotropia for which bilateral lateral rectus recessions of 7.5 mm were performed at an outside hospital at 1 year of age, followed at age 8 by resection plus transposition of the lateral rectus muscles to the orbital rim in combination with 4 mm medial rectus resections (see eSupplement). At most recent follow-up, the patient had an exotropia of 8Δ. A summary of the procedures performed for the exotropic CFEOM3 group is shown in Table 3.
Table 3.
Surgical treatments for exotropic CFEOM 3 patients
| Patient number | Procedure | ||||
|---|---|---|---|---|---|
| LR recession | Fixation of LR to lateral orbital wall | Transpose SO to MR insertion | Botox to LR | MR resection | |
| 11 | + | + | − | + | − |
| 12 | − | + | + | − | − |
| 13 | − | + | − | − | + |
| Total N (%) | 1 (33) | 3 (100) | 1(33) | 1(33) | 1(33) |
LR = lateral rectus; SO = superior oblique; MR = medial rectus; Botox = botulinum toxin
The two patients harboring the E410K AA substitution underwent eyelid surgery. In patient 11, epiblepharon repair was performed for persistent corneal issues. In patient 12, multiple ptosis procedures were performed, including frontalis slings with silicone rod suspension followed by reoperation with banked fascia lata. Patient 13 did not have ptosis surgery as he already had evidence of corneal exposure.
All CFEOM3 patients experienced some degree of exposure keratopathy and/or corneal surface disease that may or may not have been a direct consequence of corneal exposure. Patients 11 and 12 were fitted with the PROSE lens,(26) with excellent results.
DISCUSSION
CFEOM is rare, and prevalence data for CFEOM and its different subtypes are limited. One study focusing on CFEOM in the Wessex region of the UK estimated a minimal prevalence of 1/230,000 cases.(27) Because of the limited number of affected individuals, accumulating a number of cases sufficient to develop general principles of management is difficult; many patients have their first surgery performed by surgeons who have no experience operating on this condition. Consistent with this, initial surgical therapies for our 13 patients were quite variable, and their outcomes were also varied. Nevertheless, we have sought to develop a paradigm that uniquely focuses on genetic stratification. With this approach we identified several trends that we believe may guide surgical strategy or at least inform prognosis.
The CFEOM1 group included 9 patients with the KIF21A R954W AA substitution and 1 patient with the M947T AA substitution. Patients who harbored the most commonly seen R954W AA substitution underwent between 1 and 3 procedures; none had clinically significant exotropia at presentation. In contrast, the M947T patient presented with CFEOM1 with exotropia and Marcus Gunn jaw winking and has required 8 incisional strabismus procedures and 4 separate botulinum toxin injection procedures to date. The large number of procedures required occurred either because the M947T AA substitution conferred a more severe strabismus presentation, or because the patient was first treated elsewhere with several small surgeries, and then at our institution in the early days of our experience treating CFEOM. To explore these possibilities more fully, we would require a larger cohort of patients with the M947T phenotype. After undergoing a definitive medial rectus resection, he has done well. The CFEOM1 patients all required inferior rectus muscle weakening, and most also had superior oblique tenotomies with the intent of weakening both depressors of the eye. (28) We now perform this procedure routinely in CFEOM patients with severe upgaze limitation and have begun adding adjustable superior rectus resections or plications in some cases to obtain additional effect where needed. The rationale for superior rectus strengthening procedures is to provide an effect equivalent to that of a traction suture—even in patients with anomalous, dysinnervated superior rectus muscles. This overall approach is similar to that described by Ferrer.(14)
Patients who harbor the KIF21A R954W AA substitution appear to be at risk for developing exotropia after vertical rectus surgery if they are not esotropic at presentation. One hypothesis that has been offered for this phenomenon is that, following inferior rectus recessions, there is a release of their adducting effect.(12) A second possibility is that dysinnervation contributes to this phenomenon. We commonly see convergence of both eyes in attempted upgaze in R954W patients. These patients try to elevate the eyes to minimize the chin-up head position during fixation. When this occurs in a patient with a propensity for exotropia, the exotropia is masked. When surgery improves the vertical limitation, the drive to elevate the eyes (and secondarily convergence) is reduced, allowing the underlying exotropia to become manifest. Thus, when an exotropia is noted in downgaze pre-operatively (probably a pseudo-A pattern secondary to the dysinnervation described above), we counsel the family that there may be an exotropia that develops after vertical rectus surgery and that this may require an additional procedure. This finding also provides further support for performing superior oblique tenotomies, which will reduce or eliminate the A pattern and thus decrease the exotropia in downgaze.
The CFEOM3 patients differed from the CFEOM1 patients with respect to horizontal alignment and to ocular surface disease. For the CFEOM3 patients, large exotropias were present that required aggressive surgery involving fixation of the lateral rectus to the orbital wall and such measures were not needed to address horizontal strabismus in the CFEOM1 cohort. All 3 of the TUBB3 E410 patients (both E410K and E410V) had corneal exposure problems, which we believe were secondary to the weakness of facial muscles that has been described as part of the phenotype associated with E410K substitution.(4, 24) This feature likely predisposes patients to a poor blink, which may contribute to the vulnerability of the ocular surface. Alternatively, there may be corneal dysinnervation in the setting of the tubulin mutation, and pre-operative corneal sensation testing may be helpful in this regard. In either case,, the genetic confirmation of a TUBB3 mutation would direct the ophthalmologist to be more cautious regarding blepharoptosis repair and more vigilant regarding the potential for ocular surface disease.
For all CFEOM patients, because of lack of a normal Bell’s phenomenon combined with a propensity to develop corneal exposure, we recommend a modest blepharoptosis repair that uncovers enough of the pupil to allow the patient to be able to function without increasing the risk of vision loss from exposure. When both strabismus and ptosis repair were performed at our institution, we typically performed the ptosis surgery within 2 months of the strabismus surgery, and sometimes simultaneously with strabismus surgery to reduce the number of anesthetic administrations. This timing reflected that ptosis became much more symptomatic and required more urgent correction after strabismus surgery was successful in elevating the eyes. In our practice, we favor the frontalis sling with silicone rod suspension because this procedure results in a gentler lift of the eyelids that can be easily modified over time.
This study is limited in that it is a retrospective review of a limited cohort of patients treated with a variety of surgical approaches. By limiting this study to only patients with genetically confirmed CFEOM, the cohort is more uniform, but we caution that surgical decision-making for individual patients must be tempered by clinical judgment and experience. In our experience, knowledge of the genetic diagnosis provides us with at least some direction as well as perspective on areas of concern.
In conclusion, CFEOM is a complex strabismus disorder for which surgical management is difficult. In some patients, eye alignment may fail to respond to aggressive surgical intervention. We found that surgical differences occurred within CFEOM subtypes as well as between patients with KIF21A vs. TUBB3 mutations. Patients with TUBB3 mutations tended to require more robust surgery to address horizontal strabismus and were particularly susceptible to issues regarding the ocular surface, while patients with KIF21A mutations required profoundly strong vertical procedures to address upgaze limitation. As more patients with genetic diagnoses are cared for in a more uniform manner over time, it may be possible to develop additional insights and more specific and directed recommendations for surgery.
Supplementary Material
ACKNOWLEDGEMENTS:
A. FUNDING: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
B. FINANCIAL DISCLOSURES: The authors have no relevant financial disclosures.
C. The authors thank Caroline Andrews, MS, for her assistance with the genetics database search and Sheena Chew, MD, Ravikumar Balasubramanian, MD, and Irene Drmic, PhD, and Peter Kang, MD for contributing to the clinical evaluation of the patient harboring the E410V AA substitution.
REFERENCES:
- 1.Yamada K, Andrews C, Chan WM, et al. Heterozygous mutations of the kinesin KIF21A in congenital fibrosis of the extraocular muscles type 1 (CFEOM1). Nat Genet 2003;35(4):318–21. [DOI] [PubMed] [Google Scholar]
- 2.Nakano M, Yamada K, Fain J, Sener et al. Homozygous mutations in ARIX(PHOX2A) result in congenital fibrosis of the extraocular muscles type 2. Nat Genet 2001;29(3):315–20. [DOI] [PubMed] [Google Scholar]
- 3.Cederquist GY, Luchniak A, Tischfield MA, et al. An inherited TUBB2B mutation alters a kinesin-binding site and causes polymicrogyria, CFEOM and axon dysinnervation. Hum Mol Genet 2012;21(26):5484–99. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Tischfield MA, Baris HN, Wu C, et al. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell 2010;140(1):74–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Yamada K, Chan WM, Andrews C, et al. Identification of KIF21A mutations as a rare cause of congenital fibrosis of the extraocular muscles type 3 (CFEOM3). Invest Ophth Vis Sci 2004;45(7):2218–23. [DOI] [PubMed] [Google Scholar]
- 6.Cheng L, Desai J, Miranda CJ, et al. Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 2014;82(2):334–49. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Whitman MC, Engle EC. Ocular congenital cranial dysinnervation disorders (CCDDs): insights into axon growth and guidance. Hum Mol Genet 2017;26(R1):R37–R44. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Engle EC. The genetic basis of complex strabismus. Pediatr Res 2006;59(3):343–8. [DOI] [PubMed] [Google Scholar]
- 9.Graeber CP, Hunter DG, Engle EC. The genetic basis of incomitant strabismus: consolidation of the current knowledge of the genetic foundations of disease. Semin Ophthalmol 2013;28(5–6):427–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Heidary G, Engle EC, Hunter DG. Congenital fibrosis of the extraocular muscles. Semin Ophthalmol 2008;23(1):3–8. [DOI] [PubMed] [Google Scholar]
- 11.Apt L, Axelrod RN. Generalized fibrosis of the extraocular muscles. Am J Ophthalmol 1978;85(6):822–9. [DOI] [PubMed] [Google Scholar]
- 12.Brodsky MC. Surgical management of the congenital fibrosis syndrome. Am Orthoptic J 1997;47:157–63. [Google Scholar]
- 13.Crawford JS. Congenital fibrosis syndrome. Can J Ophthalmol 1970;5(4):331–6. [PubMed] [Google Scholar]
- 14.Ferrer J Congenital fibrosis of the extraocular muscles. Ophthalmol 1996;103(10):1517–9. [DOI] [PubMed] [Google Scholar]
- 15.Letson RD. Surgical management of the ocular congenital fibrosis syndrome. Am Orthoptic J 1980;30:97–101. [Google Scholar]
- 16.Merino P, Gomez de Liano P, Fukumitsu H, Franco G, Ruiz Y. Congenital fibrosis of the extraocular muscles: magnetic resonance imaging findings and surgical treatment. Strabismus 2013;21(3):183–9. [DOI] [PubMed] [Google Scholar]
- 17.Sener EC, Taylan Sekeroglu H, Ural O, Ozturk BT, Sanac AS. Strabismus surgery in congenital fibrosis of the extraocular muscles: a paradigm. Ophthalmic Genet 2014;35(4):208–25. [DOI] [PubMed] [Google Scholar]
- 18.Tawfik HA, Rashad MA. Surgical management of hypotropia in congenital fibrosis of extraocular muscles (CFEOM) presented by pseudoptosis. Clin Ophthalmol 2013;7:1–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Traboulsi EI, Jaafar MS, Kattan H, Parks MM. Congenital fibrosis of the extraocular muscles: Report of 24 cases illustrating the clinical spectrum and surgical management. Am Orthoptic J 1993;43:45–53. [Google Scholar]
- 20.Yazdani A, Traboulsi EI. Classification and surgical management of patients with familial and sporadic forms of congenital fibrosis of the extraocular muscles. Ophthalmol 2004;111(5):1035–42. [DOI] [PubMed] [Google Scholar]
- 21.Yang S, MacKinnon S, Dagi LR, Hunter DG. Superior rectus transposition vs medial rectus recession for treatment of esotropic Duane syndrome. JAMA Ophthalmol 2014;132(6):669–75. [DOI] [PubMed] [Google Scholar]
- 22.Rudolph G, Nentwich M, Hellebrand H, et al. KIF21A variant R954W in familial or sporadic cases of CFEOM1. Eur J Ophthalmol 2009;19(4):667–74. [DOI] [PubMed] [Google Scholar]
- 23.Yamada K, Hunter DG, Andrews C, Engle EC. A novel KIF21A mutation in a patient with congenital fibrosis of the extraocular muscles and Marcus Gunn jaw-winking phenomenon. Arch Ophthalmol 2005;123(9):1254–9. [DOI] [PubMed] [Google Scholar]
- 24.Chew S, Balasubramanian R, Chan WM, et al. A novel syndrome caused by the E410K amino acid substitution in the neuronal beta-tubulin isotype 3. Brain 2013;136(Pt 2):522–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Velez FG, Thacker N, Britt MT, Alcorn D, Foster RS, Rosenbaum AL. Rectus muscle orbital wall fixation: a reversible profound weakening procedure. J AAPOS. 2004;8(5):473–80. [DOI] [PubMed] [Google Scholar]
- 26.Agranat JS, Kitos NR, Jacobs DS. Prosthetic replacement of the ocular surface ecosystem: impact at 5 years. Br J Ophthalmol 2016;100(9):1171–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Reck AC, Manners R, Hatchwell E. Phenotypic heterogeneity may occur in congenital fibrosis of the extraocular muscles. Br J Ophthalmol 1998;82(6):676–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Shoshany TN, Hunter DG. Anomalous Superior Oblique Muscles in Congenital Fibrosis of the Extraocular Muscles. Manuscript under review 2019. [DOI] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
